Tags

Type your tag names separated by a space and hit enter

[Nonalcoholic steatohepatitis--current treatment options].
Przegl Lek. 2006; 63(2):91-4.PL

Abstract

Nonalcoholic steatohepatitis (NASH) is the term used to describe the distinct clinical entity in which the liver biopsy findings are similar to that observed in alcoholic hepatitis, but patients lack a history of significant alcohol consumption. The most widely supported theory implicates insulin resistance as the key mechanism leading first to hepatic steatosis, and next to steatohepatitis. In spite of lacking proof by EBM (evidence based medicine) and effective therapy for NASH, modification of risk factors, such as obesity, hyperlipidemia, and good diabetic control is generally recommended. Although there is no consensus of treatment form, the new drugs which can be useful in NASH treatment are continously tested. The aim of our study is to present current knowledge about nonalcoholic steatohepatitis, focusing on present and being in various phases of clinical trials treatment options.

Authors+Show Affiliations

Oddział Chorób Wewnetrznych z Pododdziałem Intensywnej, Opieki Kardiologicznej Szpitala Ministerstwa Spraw Wewnetrznych i Administracji w Rzeszowie. kgutski@intertele.plNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

pol

PubMed ID

16967716

Citation

Gutkowski, Krzysztof, et al. "[Nonalcoholic Steatohepatitis--current Treatment Options]." Przeglad Lekarski, vol. 63, no. 2, 2006, pp. 91-4.
Gutkowski K, Gutkowska D, Partyka M. [Nonalcoholic steatohepatitis--current treatment options]. Przegl Lek. 2006;63(2):91-4.
Gutkowski, K., Gutkowska, D., & Partyka, M. (2006). [Nonalcoholic steatohepatitis--current treatment options]. Przeglad Lekarski, 63(2), 91-4.
Gutkowski K, Gutkowska D, Partyka M. [Nonalcoholic Steatohepatitis--current Treatment Options]. Przegl Lek. 2006;63(2):91-4. PubMed PMID: 16967716.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Nonalcoholic steatohepatitis--current treatment options]. AU - Gutkowski,Krzysztof, AU - Gutkowska,Dorota, AU - Partyka,Mariusz, PY - 2006/9/14/pubmed PY - 2006/12/29/medline PY - 2006/9/14/entrez SP - 91 EP - 4 JF - Przeglad lekarski JO - Przegl Lek VL - 63 IS - 2 N2 - Nonalcoholic steatohepatitis (NASH) is the term used to describe the distinct clinical entity in which the liver biopsy findings are similar to that observed in alcoholic hepatitis, but patients lack a history of significant alcohol consumption. The most widely supported theory implicates insulin resistance as the key mechanism leading first to hepatic steatosis, and next to steatohepatitis. In spite of lacking proof by EBM (evidence based medicine) and effective therapy for NASH, modification of risk factors, such as obesity, hyperlipidemia, and good diabetic control is generally recommended. Although there is no consensus of treatment form, the new drugs which can be useful in NASH treatment are continously tested. The aim of our study is to present current knowledge about nonalcoholic steatohepatitis, focusing on present and being in various phases of clinical trials treatment options. SN - 0033-2240 UR - https://www.unboundmedicine.com/medline/citation/16967716/[Nonalcoholic_steatohepatitis__current_treatment_options]_ L2 - https://medlineplus.gov/cirrhosis.html DB - PRIME DP - Unbound Medicine ER -